TP53 and breast carcinoma: This strategy may also be robustly extended toother tumorigenic drivers (e.g., MYC) and tumor suppressors (e.g.,p53) in PCa and other cancer types, such as breast cancer, non-smallcell lung cancer, and hepatocellular carcinoma.